<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001959</url>
  </required_header>
  <id_info>
    <org_study_id>000042</org_study_id>
    <secondary_id>00-DK-0042</secondary_id>
    <nct_id>NCT00001959</nct_id>
  </id_info>
  <brief_title>Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)</brief_title>
  <official_title>Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness of the drug pirfenidone in treating focal segmental&#xD;
      glomerulosclerosis (FSGS). Patients with this disease have kidney fibrosis (scarring) and&#xD;
      proteinuria (excessive excretion of protein in the urine). About half of patients with FSGS&#xD;
      eventually require kidney dialysis or transplant. Steroids, which are currently used to treat&#xD;
      the disease, are effective in only a minority of patients. Other drugs, such as cyclosporin&#xD;
      and cyclophosphamide, improve proteinuria in a very small percentage of patients and have&#xD;
      serious side effects.&#xD;
&#xD;
      Patients with FSGS who wish to participate in this study will undergo pre-study evaluation&#xD;
      with blood and urine tests. Patients must be on a stable dose of an ACE inhibitor (a drug&#xD;
      that lowers blood pressure and reduces proteinuria) for at list 6 months before starting&#xD;
      pirfenidone therapy. (Patients who are not already taking an ACE inhibitor will be started on&#xD;
      the drug; those who cannot tolerate ACE inhibitors will be given a different drug.) Patients&#xD;
      with elevated cholesterol will take a cholesterol-lowering drug. A diet containing&#xD;
      approximately 1 gram of protein per kilogram of body weight per day will be recommended.&#xD;
&#xD;
      Patients will take pirfenidone by mouth 3 times a day for 12 months. Blood and urine will be&#xD;
      tested once a month, either at NIH or by the patient's local kidney specialist. They will&#xD;
      collect two 24-hour urine samples at the beginning of the treatment period, at 2-month&#xD;
      intervals throughout the study, and at a 6-month follow-up. Patients will also be asked to&#xD;
      give three to five tubes of blood and urine samples for analysis during the study.&#xD;
&#xD;
      In animal studies, pirfenidone improved kidney function and proteinuria and reduced kidney&#xD;
      scarring in rats with a disease similar to FSGS. In human studies, pirfenidone improved&#xD;
      breathing and survival in patients with lung fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this pilot phase II trial is to evaluate the ability of pirfenidone, a novel&#xD;
      anti-fibrotic agent, to reduce the proteinuria and slow the rate of progression of renal&#xD;
      insufficiency in patients with focal segmental glomerulosclerosis (FSGS). We will enroll 25&#xD;
      patients with renal biopsy proven FSGS and evidence of impaired renal function (glomerular&#xD;
      filtration rate, GFR, of 10-80 ml/min; after 1/02 must have GFR greater than 25 ml/min) as&#xD;
      assessed by the 4 variable Modification of Diet in Renal Disease equation. As standard of&#xD;
      care therapy, all patients will also receive angiotensin converting enzyme inhibitor (ACEI)&#xD;
      therapy, and will receive an HMG Co-A reductase inhibitor drug if hypercholesterolemic.&#xD;
      Preliminary evaluation will assure that the patients meet the study requirements, and an&#xD;
      evaluation period will be used to ensure that patients are on maximal conservative therapy&#xD;
      prior to the baseline period. Patients will receive treatment with pirfenidone daily, with&#xD;
      dose adjusted for body weight and level of kidney function. The primary end point will be the&#xD;
      decrease glomerular filtration as a marker of glomerular injury; reduction in proteinuria&#xD;
      will be a secondary end-point. If the pilot study suggests this drug delays progression of&#xD;
      renal insufficiency or reduces proteinuria in patients with FSGS, we will proceed with a&#xD;
      large scale randomized, placebo-controlled study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in GFR During Treatment Period</measure>
    <time_frame>12 months from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proteinuria After Treatment</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Positive Change in GFR</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Fibrosis</condition>
  <condition>Focal Glomerulosclerosis</condition>
  <condition>Kidney Failure</condition>
  <condition>Nephrotic Syndrome</condition>
  <condition>Proteinuria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Adults greater than or equal to 18 years of age.&#xD;
&#xD;
               2. Patients will provide informed consent.&#xD;
&#xD;
               3. Biopsy proven FSGS.&#xD;
&#xD;
               4. Glomerular filtration rate of at least 25 and no more than 80 ml/minute as&#xD;
                  assessed by the 4 variable Modification of diet in renal disease GFR equation.&#xD;
&#xD;
               5. At least 6 months of renal function data must be available prior to the patient's&#xD;
                  receiving pirfenidone, and renal function must show a rate of decline of greater&#xD;
                  than or equal to 0.4 ml/min/month during this baseline period.&#xD;
&#xD;
               6. Patients must have received no glucocorticoids, cyclophosphamide, mycophenolate&#xD;
                  or other immunosuppressive drugs for at least 2 months prior to the study period.&#xD;
&#xD;
               7. Patients must have received no cyclosporin for at least 6 months prior to the&#xD;
                  study period.&#xD;
&#xD;
               8. Patients must have been taking an angiotensin converting enzyme inhibitor (ACEI)&#xD;
                  or angiotensin receptor blocker (ARB) at a stable dose for at least 6 months,&#xD;
                  unless intolerant of both classes of medication.&#xD;
&#xD;
               9. Patients who are HIV seropositive will receive standard care for HIV disease&#xD;
                  (patients receiving immune-modulating therapy will be excluded).&#xD;
&#xD;
              10. Women with child-bearing potential must maintain an effective birth control&#xD;
                  regimen (oral contraceptive, intrauterine device, barrier plus spermicide).&#xD;
&#xD;
              11. Men will be advised that although Ames testing has been negative for any evidence&#xD;
                  of mutagenicity, they should consider use of contraceptives during the study&#xD;
                  period as well.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Inability to give informed consent or cooperate with study.&#xD;
&#xD;
          2. Known intolerance to pirfenidone.&#xD;
&#xD;
          3. Evidence of FSGS associated with an additional primary or secondary glomerular disease&#xD;
             (e.g. diabetes, membranous nephropathy, IgA nephropathy).&#xD;
&#xD;
          4. Recent (within 6 months) history of myocardial infarction.&#xD;
&#xD;
          5. History of peptic ulcer within 6 months.&#xD;
&#xD;
          6. History of cerebrovascular disease manifested by transient ischemic attack or&#xD;
             cerebrovascular accident within 6 months.&#xD;
&#xD;
          7. Pregnancy, breast feeding or inadequate birth control.&#xD;
&#xD;
          8. History of photosensitivity dermatitis.&#xD;
&#xD;
          9. Concurrent drug treatment with gemfibrozil, cyclosporin or erythromycin,&#xD;
             potassium-sparing diuretics and other drugs which may potentiate hyperkalemia, or&#xD;
             concurrent immunosuppresive medications.&#xD;
&#xD;
         10. Requirement for NSAID therapy.&#xD;
&#xD;
         11. Requirement for interleukin-2 therapy or other immune-modulating medication.&#xD;
&#xD;
         12. Existence of any other condition which would complicate the implementation or&#xD;
             interpretation of the study.&#xD;
&#xD;
         13. Renal transplant.&#xD;
&#xD;
         14. Evidence of significant hepatic disease, as indicated by serum transaminases greater&#xD;
             than 3 times upper limit of normal, protime greater than 2 seconds prolonged.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/B_2000-DK-0042.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Abbate M, Zoja C, Rottoli D, Corna D, Perico N, Bertani T, Remuzzi G. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol. 1999 Apr;10(4):804-13. doi: 10.1681/ASN.V104804.</citation>
    <PMID>10203365</PMID>
  </reference>
  <reference>
    <citation>Bodi I, Kimmel PL, Abraham AA, Svetkey LP, Klotman PE, Kopp JB. Renal TGF-beta in HIV-associated kidney diseases. Kidney Int. 1997 May;51(5):1568-77. doi: 10.1038/ki.1997.215.</citation>
    <PMID>9150474</PMID>
  </reference>
  <reference>
    <citation>Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994 Nov 10;331(19):1286-92. doi: 10.1056/NEJM199411103311907. No abstract available.</citation>
    <PMID>7935686</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>January 18, 2000</study_first_submitted>
  <study_first_submitted_qc>January 18, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2000</study_first_posted>
  <results_first_submitted>June 16, 2010</results_first_submitted>
  <results_first_submitted_qc>April 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2012</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Jeffrey Kopp, M.D.</investigator_full_name>
    <investigator_title>Staff Clinician</investigator_title>
  </responsible_party>
  <keyword>Fibrosis</keyword>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Renal Failure</keyword>
  <keyword>TGF-Beta</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <keyword>FSGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>21 adults patients were enrolled between 2000-2004 at the clinical center of NIH</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pirfenidone</title>
          <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>newly diagnosed colon cancer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disabling sedation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pirfenidone</title>
          <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline GFR</title>
          <units>ml/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline period proteinuria</title>
          <units>g/d</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" lower_limit="1.6" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Decrease in GFR during baseline period</title>
          <units>ml/min/1.73 m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.61" lower_limit="-1.31" upper_limit="-0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of angiotensin antagonist therapy before treatment</title>
          <description>2 patients did not receive angiotensin antagonist therapy during the baseline periods because of angioedema and hypotension.</description>
          <units>month</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="8.4" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decrease in GFR During Treatment Period</title>
        <time_frame>12 months from baseline</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in GFR During Treatment Period</title>
          <population>ITT</population>
          <units>ml/min/1.73 m2</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" lower_limit="-0.78" upper_limit="-0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H0: GFR Decrease during baseline period and treatment period are same</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proteinuria After Treatment</title>
        <time_frame>12 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
          </group>
        </group_list>
        <measure>
          <title>Proteinuria After Treatment</title>
          <units>g/d</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="1.2" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H0: Proteinuria during baseline and treatment periods are same</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Positive Change in GFR</title>
        <time_frame>12 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Positive Change in GFR</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 months</time_frame>
      <desc>Include all adverse events either judged to be related to the study or unrelated to the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Pirfenidone</title>
          <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colon cancer (unrelated to the trial)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated liver enzymes (judged possibly related to the trial)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Death (unrelated to the trial)</sub_title>
                <description>traumatic subdural hematoma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation or fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>photosensitivity dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No control group, measurement imprecision, results may not applicable to all patients with FSGS, needs histologic evidence to support our findings, Optimal dosage needs to be identified.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey B Kopp, MD</name_or_title>
      <organization>NIDDK, NIH</organization>
      <phone>3015943403</phone>
      <email>jbkopp@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

